title: [Effects of growth hormone replacement therapy on bone metabolism].
abstract: Growth hormone (GH) as well as insulin like growth factor-1 (IGF-1) are essential hormones to maintain homeostasis of bone turnover by activating osteoblastogenesis and osteoclastogenesis. Results from GH replacement therapy for primary osteoporosis and adult-onset GH deficiency (AGHD) suggest that one year or more treatment period by this agent is required to gain bone mineral density (BMD) over the basal level after compensating BMD loss caused by dominant increase in bone resorption which was observed at early phase of GH treatment. A recent meta-analysis demonstrates the efficacy of GH replacement therapy on increases in BMD in male patients with AGHD. Additional analyses are needed to draw firm conclusions in female patients with AGHD, because insufficient amounts of GH might be administrated to them without considerations of influence of estrogen replacement therapy on IGF-1 production. Further observational studies are needed to clarify whether GH replacement therapy prevent fracture risk in these patients.
authors.affiliation: Internal Medicine 1, Shimane University Faculty of Medicine, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Toshitsugu
authors.initials: T
authors.lastname: Sugimoto
mesh_terms: D001842:Bone and Bones / Q000378:metabolism*; D005598:Fractures, Spontaneous / Q000517:prevention & control; D020249:Hormone Replacement Therapy; D019382:Human Growth Hormone / Q000172:deficiency* / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D015201:Meta-Analysis as Topic; D010006:Osteoblasts; D010010:Osteoclasts; D010024:Osteoporosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I